Prognostic value of the neutrophil-to-lymphocyte ratio for hepatocellular carcinoma patients with portal/hepatic vein tumor thrombosis

Figure 3 Disease-free survival of patients in the four groups according to the Cancer of the Liver Italian Program score. The median disease-free survival duration in each group was 7.9, 2.3, 1.5, and 2.3 mo, respectively (from 1 to 4, P = 0.039). CLIP: Cancer of the Liver Italian Program.